PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/07/2024 BST			5-day change	1st Jan Change
34.17 ^USD	+3.14%		+8.30%	+23.98%

07-09	RBC Cuts Price Target on PTC Therapeutics to $32 From $39, Keeps Sector Perform Rating	MT
07-01	Cantor Fitzgerald Raises Price Target on PTC Therapeutics to $62 From $52, Maintains Overweight Rating	MT

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year of Fiscal 2021

January 11, 2021 at 12:06 pm

PTC Therapeutics, Inc. provided revenue guidance for the full year of fiscal 2021. The company anticipates full year net product revenues for the DMD franchise to be between $355 million and $375 million.

Latest news about PTC Therapeutics, Inc.

RBC Cuts Price Target on PTC Therapeutics to $32 From $39, Keeps Sector Perform Rating	07-09	MT
Cantor Fitzgerald Raises Price Target on PTC Therapeutics to $62 From $52, Maintains Overweight Rating	07-01	MT
PTC Therapeutics Shares Drop After Negative Opinion on Muscular Dystrophy Treatment	06-28	MT
PTC Therapeutics Shares Drop After Negative Opinion on Muscular Dystrophy Treatment	06-28	MT
BofA Securities Adjusts PTC Therapeutics Price Target to $32 From $25, Maintains Underperform Rating	06-21	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	06-20	MT
PTC Therapeutics Reports Favorable Interim Results in Huntington's Disease Study; US FDA Lifts Clinical Hold	06-20	MT
Transcript : PTC Therapeutics, Inc. - Special Call	06-20
PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients	06-20	CI
Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing	05-24	MT
Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating	05-21	MT
Raymond James Upgrades PTC Therapeutics to Market Perform From Underperform	05-20	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	05-20	MT
Sector Update: Health Care	05-20	MT
PTC Therapeutics Says European Commission Seeking Review of Negative Opinion on Translarna	05-20	MT
Transcript : PTC Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM	05-16
Sector Update: Health Care Stocks Steady Premarket Tuesday	05-14	MT
Sector Update: Health Care	05-14	MT
PTC Therapeutics Gets FDA Priority Review for Upstaza Biologics License Application	05-14	MT
PTC Therapeutics Gets FDA Priority Review of Upstaza Gene Therapy	05-14	DJ
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza	05-14	CI
North American Morning Briefing : More Earnings -2-	04-30	DJ
Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	04-29	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	04-26	MT
Sector Update: Health Care	04-26	MT

Chart PTC Therapeutics, Inc.

Duration

Period

More charts

Company Profile

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Sector

Biotechnology & Medical Research

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for PTC Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

34.17 USD

Average target price

38.33 USD

Spread / Average Target

+12.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PTC THERAPEUTICS, INC.	+23.98%	2.54B
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs